Reddit Posts
Bullish on $NRXP 🚨 ✅ Commercial ketamine manufacturing initiated ✅ FDA feedback reportedly only “minor” admin items remaining ✅ Positioned for potential approval this summer ✅ Addressing ongoing ketamine shortages Undervalued mental health biotech with real momentum building. 💊📈
Thoughts on NRXP after Trump’s psychedelic/FDA executive order?
$NRXP News Update :NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
$NRXP - Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.
$NRXP - NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research.
$NRXP - The January 26, 2026 deadline will also apply in determining whether a stockholder proposal or nomination is timely for purposes of exercising discretionary voting authority under Rule 14a-4(c) of the Exchange Act.
How to check if the company you like is going bankrupt! (NXXT, BURU, etc)
NRXP: FDA Decision Dec 31 + 38% Short Spike = Potential Binary Catalyst. Here's the Due Diligence.
Why Bristol Myers Squibb Should Buy NRXP
NRX-101 + Transcranial Magnetic Stimulation (TMS) for NRx Pharmaceuticals (NRXP)
$NRXP HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
Earnings Week Breakdown: What’s Coming Friday Through Tuesday (NXXT, NRXP, CAN and more)
$NRXP HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
NRX Pharmaceuticals, Inc. (ticker: NRXP)
$NRXP - NRx Pharmaceuticals is making NRX-100 available on an expanded access basis upon physician request for patients with serious or life-threatening suicidal depression despite treatment with currently available therapy.
$NRXP - Dura Medical, together with pending acquisitions of Neurospa TMS and Cohen & Associates, to provide contiguous coverage at more than 8 locations along Florida’s West Coast, with planned coverage throughout the Florida Peninsula
NRx Pharmaceuticals (NRXP) -- Is anyone seeing a pattern here? Third analyst enters, and now with a $40 price target ... AND ... NRx's HOPE Therapeutics closes on Dura Medical clinic acquisition in Florida! This journey is quickly unfolding per plan. Comprehensive post link below. A WINNER HERE!
NRx Pharmaceuticals (NRXP) -- Recently posted the newly updated price targets of $25 and $34. Another significant PR today - they keep coming! Potential to make an excellent return on a current $2.60 share price. Consider making a DECISION TO BE A PART OF this incredible mission; IT IS HAPPENING!
I accidentally bought nrxp stock for 2.32, is it alright?
My Top 5 Watchlist: Price Targets and Triggers
Top 5 Mixed Cap Blend (For Diversified Degens)
Top 5 Friday Radar-Catalysts And Clear Levels
NRXP – Why NRX-100 Might Be the Most Asymmetric Play in Biotech Right Now
Today, price target for NRx Pharmaceuticals (NRXP) upgraded once again by BTIG, which shows even greater confidence in probability of success. The outstanding list of Q2 accomplishments and status with the FDA are obviously very compelling.
NRx Pharmaceuticals (NRxP) - After very recent earnings call, probability of success and price target raised -- background included in this post. The time is drawing near!
Top 5 For Traders: Breakouts, Rebounds, And A Round-Number Flip
Reddit Ticker Mentions - AUG.20.2025 - $PLTR, $INTC, $NVDA, $UNH, $OPEN, $WWR, $AMD, $ADD, $DFLI, $NRXP
Reddit Ticker Mentions - AUG.20.2025 - $PLTR, $INTC, $NVDA, $UNH, $OPEN, $WWR, $AMD, $ADD, $DFLI, $NRXP
NRx Pharmaceuticals (NRXP) has made outstanding progress in Q2 2025 (results below) and is setting up for an FDA approval decision in the near term
Reddit Ticker Mentions - AUG.18.2025 - $UNH, $ASTS, $RDDT, $NVDA, $RKLB, $PLTR, $BYD, $NBIS, $ONDS, $NRXP
Reddit Ticker Mentions - AUG.18.2025 - $UNH, $ASTS, $RDDT, $NVDA, $RKLB, $PLTR, $BYD, $NBIS, $ONDS, $NRXP
NRx Pharmaceuticals (NRxP) -- This one is LIVE! Analysts just upgraded their targets to $21 and $31 based on Fast Track granted by FDA this week. Has two drugs that address the national crisis of suicidal ideation in depression, including bipolar depression. Aiming for PDUFA/approval in 2025.
$NRXP - announces that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 4:30pm ET the same day. h
$NRXP - Cohen is one of the premier Interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation ("TMS") as well as medication management.
I posted about SPRO before it ran. NRXP is next. Up twenty five percent already since I posted with June 30 PDUFA coming
I called SPRO before it ran. Now NRXP is next. Up 25% already since I posted with June 30 PDUFA coming
$NRXP - Pharma stock on the cusp of FDA approval
What is going on with NRXP stock ?
NRXP – Tiny Biotech Just Scored $10.3M to Launch National Ketamine/TMS Mental Health Chain – Starting With VA-Approved Clinics
$NRXP - The terms of the Series A Preferred will be defined in a Certificate of Designation to be filed with the State of Delaware, and expected to provide for, among other things, a dividend based on current market conditions and the right to appoint a director to HOPE's Board.
$NRXP - Delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients
$NRXP - The Term Sheet, which is non-binding and subject to the execution of a definitive Stock Purchase Agreement, contemplates an investment of $2.5 million to purchase Series A Convertible Preferred Stock (the "Series A Preferred") at a $50 million pre-money valuation.
$NRXP HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: $NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
$NRXP - The Term Sheet, which is non-binding and subject to the execution of a definitive Stock Purchase Agreement, contemplates an investment of $2.5 million to purchase Series A Convertible Preferred Stock (the "Series A Preferred") at a $50 million pre-money valuation.
FULL Nasdaq Article by Ari Zoldan: How Three Companies Are Taking Aim at Alleged Naked Short Sellers - 28 Nov 2023 - (immortalized in photos + links)
NRXP FDA provided Written Responses on January 10 th. As previously announced in October 2022 , an updated NRX-101 module 3 was submitted to add the intended commercial manufacturer to the IND. With FDA's written response, it appears that NRx Pharmaceuticals has reached alignment with the FDA
BREZ has the best risk/reward for SPACs since CCIV in 2021 at $12, low float with huge call OI for May + gamma squeeze potential
It’s criminal for Fauci to delay approval of Zyesami from $NRXP and $RLFTF. Now Ted Cruz is all over it to make sure it happens…link below. This needs to be all over Fox News, joe Rogan, etc ASAP
Senator Ted Cruz pressing Fauci for why RLFTF (relief) and NRXP’s Zyesami hasn’t gotten eua yet and is saving lives from covid!!!!. Guys you need to see this. This needs fo be blasted ALL over the news. This is criminal what the FDA does. PLEASE READ the link below. CONGRESS is all over this!!!!
NRXP, 673K shares bought by someone, Zyesmi works for COVID patients
NRXP Short Volume 55%, Is it setting up for a squeeze?
NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge
NRx Pharmaceuticals (NRXP) CEO to Provide Business Update on January 10th
Relief Therapeutics (RLF.SW, RLFTF) Is flying again today, NRXP will follow too.
Proud holding Relief Therapeutics (RLF.SW, RLFTF) & NRXP! https://miamicourant.com/stories/617928153-op-ed-the-emergency-use-law-should-be-used-for-emergencies-like-now
Relief Therapeutics (RLF.SW, RLFTF) flying today 46% and more to come🤞, NRXP just released a PR for a new EUA submission. With this one approved both of them will have a huge run!
NRXP Stock Rumbles On Request For Therapy Designation.
NRXP NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil)
NRXP 0 shares available, has filled gap back down after its covid variant vaccine PR. Said they will be testing on new variant
$NRXP Zyesemi and BriLife is the Covid19 game changer. Don’t miss on this one (like I almost missed LGVN).
Play for tomorrow is BMTX and NRXP 🚀🚀🎉🎉🎰🎰 Don’t miss this one out!!
NRXP- held up nicely today as still 23% up from Friday close
NRXP Covid Vaccine don't sleep on it, I see it squeezing back to high 9s 😉💥
CONFUSED! NRXP Study looks towards EUA but price still falling? Any Medical People know why?
NRXP Stock: Aviptadil Effective In Increasing COVID Recovery Odds & Surv...
$NRXP is the play, 23M float, 4.5% short of float (Finviz).
NRXP NEWS Out! Low float, FDA Pending Up Pre-Market!
NRXP 💥 💥 Great PR today, this can go easily to 100$ 🚀 🚀
NRXP - the covid vaccine that may be able to evolve to combat different variants
NRXP anyone, 50% today was even at 80% intraday? Vaccine for Covid plus a potential therapeutic Zyesami/aviptadil (currently in NIH trial h2h with Remdesivir). Good news today from their vaccine trials and seems that this beauty can run fast 💥 💥
Mentions
NRXP looking good in the after hours!!
NRXP looking good at overnight market 👀
FDA submission soon - you won’t want to miss NRXP! Let’s go to 6 soon.
I beg you guys.. take a look at NRXP.. it should be good for you
NRXP algorithm triggered. Time for a bounce!!
I called NRXP at 3.4, 3.6 and now 3.95. Next target I guessing it would be 5. Come on you NRXP peeps!
NRXP to 4 is within possibility!! Military stock + biomed?!? NRx Pharmaceuticals reported significant progress in the first quarter of 2026, including anticipated FDA approval for its preservative-free ketamine product, KETAFREE, expected by Q3 2026 amid positive preliminary evaluations from the FDA. The company has begun commercial manufacturing at a rate of one million doses per month and secured favorable FDA feedback during a Type C meeting. The launch of NRX-101, an adjunct therapy for Transcranial Magnetic Stimulation (TMS), is also on track, supported by non-dilutive federal funding. Key appointments, such as Prof. Joshua Brown as Chief Medical Innovation Officer, and the establishment of NRx Defense Systems, Inc. for military applications further enhance NRx's capabilities.
Analysts estimate $NRX Pharmaceuticals (NRXP.US)$ to post revenue of USD25.57M for 2026Q1, EPS is estimated to be USD0.288. The accounting standard used for the above data is US-GAAP.
Don’t sleep on NRXP…. I sense some insider buys
WILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2026 financial results before the market opens on Monday, May 18, 2026 via press release, which will be available on the Company's website at . The Company will host a conference call at 8:00am ET the same day.
$NRXP Ketamine FDA approval possible this summer
How long have you been in NRXP? Not many people know or even follow it, at least from what I have seen.
NRXP is a good stock to get into it aligns perfectly for this
Here is a timeline of the key events: * **March 17, 2026:** The FDA's Office of Generic Drugs issued a favorable **bioequivalence determination** for NRx's ketamine product. * **April 16, 2026:** The White House issued an **Executive Order** directing the expedited approval of drugs to treat severe depression, suicidality, and PTSD. This executive order was specifically cited by the company as a factor in its discussions with the FDA. * **April 21, 2026 (After Market Close):** NRx announced it received a positive **Discipline Review Letter** from the FDA's Office of Generic Drugs. The letter covers the drug's quality, including manufacturing and microbiology, and requests only **"minor" administrative changes**. * The company also met with FDA leadership, who expressed **support for approval within the current review cycle**, targeting a final approval decision in **Summer 2026**. * The U.S. Department of Veterans Affairs has identified ketamine as **"medically necessary"** for treating suicidality and treatment-resistant depression * FORECAST * the stock has responded positively to this news. * **Performance:** Shares posted a **17% return over the last week** following the regulatory updates. * **Market Data:** As of April 22, 2026, NRXP has a market capitalization of approximately **$97.5 million**. Analysts forecast **67% revenue growth for fiscal 2026**, with expectations for the company to achieve profitability this year after recent losses
What happen to NRXP? Why it went up by 15%?!
NRXP with both defence and biomed catalysts?!
NRXP LETS GOOOO NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the appointment of Glenn Tyson as the company's first Chief Commercial Officer. As NRx looks forward to the anticipated approval of its Abbreviated New Drug Application for their preservative-free ketamine product, it looks to build its commercial capabilities and prepare for a successful launch.
NRXP!! NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Appointment of Glenn Tyson as the Company’s First Chief Commercial Officer Commercialisation will make this company go booooooommmm
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year -HUBC: $920k cash vs $129.5m in current liabilities
For a dead cat bounce or short term play, you guys can consider LNKS, its making moves in the overnight market. Longer term u can consider NRXP
NRXP still moving strong
NRXP is slowly slowly heading upwards. Potential re rating soon!!
NRXP CGTX!!! Lets go FEMY BOIS
is anyone in NRXP? [https://www.tradingview.com/news/reuters.com,2026:newsml\_L8N40C1JP:0-nrx-pharmaceuticals-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/](https://www.tradingview.com/news/reuters.com,2026:newsml_L8N40C1JP:0-nrx-pharmaceuticals-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/)
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
Yes! I'm invested in a few other cancer stocks that could go high based on current share price - MAIA, AUTL, CHRS. But IOVA is a strong contender. Outside of that I'd bet DVLT, NRXP and FEMY (heavy on this choice because they have so much going for them).
NRXP news today is legit. Its a speculative 2-4 year play.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
Y'all are still shilling this one eh? - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
Waiting for MIST, NRXP, and AUID for news. One of these days.
NRXP watch for approval timeline
I bought $NRXP at the peak thinking the Jan 26 deadline meant something bullish would happen. Turns out it's just SEC compliance theater. At least I mapped the damage here: [$NRXP](https://aimytrade.io/s/NRXP?utm_source=reddit&utm_medium=comment&utm_campaign=RobinHoodPennyStocks&utm_term=NRXP&utm_content=variant_1771448538690_m30cf6)
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
NRXP has to pull out of the hole it got dropped in. It was holding solid over $2.
NRXP and CABA looking good rn!!
How t f are you making money with NRXP? it's been a bloodbath from the beginning..I seriously have the CEO, but can't sell yet, too far down
I've followed NRXP for a while. No way you 2.5 call on that is in the money like youre showing. Fake.
*SCAM ALERT* The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert • NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution • BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution • NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution • OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. • MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
Here are some examples of commonly posted/pumped stocks will horrendous balance sheets. I anticipate every single one of these companies will massively dilute shareholders within the next 6-12 months in an attempt to stay afloat. I doubt it'll work. NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
LMAO more dilutive debt. Ontop of: The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert • NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution • BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution • NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution • OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. • MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
NRXP is bottoming on 36x their 90 day average volume on news that they’re trying to accelerate FDA approval 👀
Hopefully I can nab some at open NRXP - submitted 70,000 real world patient reviews datset with their already submitted fda application
NRXP! Mark my words it will be a 10 bagger in 2 years time
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
I'm not sure what to tell you at this point lol. I will just plug my usual copy+paste. Be careful with holding any of these guys for any meaningful amount of time The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
NRXP. I've mentioned it multiple times in other subs. Preservative free ketamine with positive results. Expected FDA approval in the summer. They've got another promising drug in the pipeline. Huge 10x potential.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively I floated by goodwill.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. -ASBP: $1.95m in cash and $13.86m in debt/payables due this year -SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. **Was $41m, but they diluted to pay off debt
I appreciate the general advice on checking balance sheets. That's always good practice. I did notice, though, that you updated your post after someone pointed out NRXP recently cleared their debt, yet they're still included on this list. I've also seen similar posts from you in a few other threads. Beyond the debt situation, NRXP just announced a joint offering with neurocare Group AG for neuroplastic therapy targeting depression. That was just yesterday. They're also advancing NRX-101 through the FDA pipeline. This doesn't exactly fit the profile of a company waiting for a pump to dump shares before bankruptcy. Not making accusations, but when the facts have changed and the narrative hasn't, it's fair to ask: is there a short position here that's getting uncomfortable with the momentum?
REMINDER! The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
There are so many every day that I've genuinely gotten bored of reposting lol The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
NRXP and ASBP both waiting on FDA feedback that is a few days overdue.
NRXP is also late on FDA news.
Didn't NRXP recently pay off their debt?
Good post. As a fellow scam hater, I feel this is an appropriate place to share my Big List of Stupid Balance Sheets: The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
Thanks for sharing this detailed analysis! The potential for a short squeeze with NRXP is intriguing, especially given the upcoming FDA decision and the comparison to OMER's past performance. The fact that the company is actively expanding clinics and eliminating debt adds to the positive outlook. With such a clearly defined timeline and
All of these analysts, with the exception of one (I think), have abysmal success rates. Every last one of them doesn't have a rate of return that comes ANYWHERE near what they are projecting the gain to be on NRXP. That's to say that their average return would be materially impacted by this one stock, but all of their average returns are awful. Which lends to the fact that HC Wainwright always issues absurd price targets and the stocks never see them, as reflected in the analysts average rate of return.
Love this question. First, that PT is just one analysts PT. The average is $36.75 but that's neither here nor there. Now to the nuts and bolts of that absolutely ABSURD PT. The analysts that have PTs issued on the stock ALL have a conflict of interest. The representation comes from HC Wainwright (notorious for issuing PTs that could pass as being issued by someone smoking crack), BTIG (serves as a financial advisor and acquisition advisor), D Boral Capital (performed shelf offerings for NRXP), and Ascendiant Capital (assists in capital raises/financing solutions). It quite literally best serves them to effectively sell the stock as this pipedream that it very much is not so that they can achieve optimal outcomes for them via the other services they provide NRXP. Also, NRXP makes sure to publish each of the "research reports" on their website so you can easily access the reports that "support" these PTs that aren't rooted in reality in the slightest. It's not a common practice amongst companies that are confident in their outcomes. Also, it's important to note these are 12 month price targets and the price target has been at the same place since like 2022 and just gets reiterated 100 times over. So instead of 12 months, you can really call it a 48 month target. Also, by my estimation, I think you will be lucky to see the stock hit even the low end of the range ($25) for more than 30 minutes when it does jump upon approval should it happen. Shorts will cover and spike it artificially but then I think it comes back to $7.50 in the end.
NXXT shills out in full force again today. Don't forget.. The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.